stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Free cash flow
GeneDx Holdings Corp.'s free cash flow for fiscal 2025 was $14.3M, compared with −$34.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$75.8M. Over the past ten years it has ranged from −$333.5M (fiscal 2022) to $14.3M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 3 consecutive fiscal years. GeneDx Holdings Corp. ranks 45th of 49 Diagnostics & Research companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $14.3M | — |
| FY2024 | −$34.0M | — |
| FY2023 | −$181.8M | — |
| FY2022 | −$333.5M | — |
| FY2021 | −$211.2M | — |
| FY2020 | −$125.1M | — |
| FY2019 | −$34.2M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$39.1M | — |
| Mar 2026 | −$38.9M | — |
| Dec 2025 | −$7.4M | — |
| Sep 2025 | $9.6M | 19.18% |
| 21 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| VCYT Veracyte, Inc. compare | $161.9M |
| CDNA CareDx, Inc. compare | $59.8M |
| CSTL Castle Biosciences, Inc. compare | $4.0M |
| FRNM Freenome, Inc compare | −$907.1K |
| ADPT Adaptive Biotechnologies Corporation compare | −$8.8M |
| NEO NeoGenomics, Inc. compare | −$26.5M |
| WGS GeneDx Holdings Corp. | −$75.8M |
| PSNL Personalis, Inc. compare | −$97.6M |
| OPK OPKO Health, Inc. compare | −$135.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement